Related Experiment Video
Updated: Jun 12, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
Prevention of NMDA receptor sensitization by neurotoxic β-amyloid through polyphosphate coacervation
Werner E G Müller1, Sanja Perovic-Ottstadt1, Rita Dobmeyer2
1ERC Advanced Investigator Grant Research Group at the Institute for Physiological Chemistry, University Medical Center of the Johannes Gutenberg University, Mainz 55128, Germany.
Abstract:
Alzheimer's disease is characterized by amyloid-β (Aβ)-induced synaptic dysfunction and N-methyl-d-aspartate (NMDA) receptor-dependent calcium dysregulation, and inorganic polyphosphate (polyP), a platelet-enriched polymer released upon platelet activation, has emerged as a potential modulator of neuronal survival. Primary rat neuronal cultures and PC12 pheochromocytoma cells were exposed to the neurotoxic Aβ fragment Aβ(25-35), following a 2-5 day pre-incubation to induce its toxic conformation; neuronal apoptosis, NMDA receptor-mediated calcium influx, and the mechanistic basis of polyP action were assessed in the presence of sodium polyphosphate (Na-polyP), including experiments with calcium-chelating polyP coacervates formed in combination with serotonin, and the release kinetics of three polyP-based brain-targeted formulations were characterized. Pre-incubated Aβ(25-35) at 10 µM induced apoptotic neuronal death within 3 days, whereas coincubation with Na-polyP (50 µg/mL) abolished Aβ-induced neurotoxicity and significantly attenuated glutamate-evoked NMDA receptor-dependent calcium influx; mechanistic analyses demonstrated that Na-polyP forms calcium-chelating coacervates, promoted by serotonin at physiological Ca²⁺ concentrations, and that polyP nanogels, nanoparticles and micelle-based formulations exhibit controlled release profiles. These data identify calcium chelation via polyP coacervate formation as a key mechanism underlying protection against Aβ-induced NMDA receptor sensitization and neuronal death, and suggest that polyP-based strategies may provide a mechanistically grounded approach for therapeutic intervention in Alzheimer's disease.
Insights
Inorganic polyphosphate (polyP) protects against Alzheimer's disease by chelating calcium, preventing amyloid-beta-induced neuronal death and N-methyl-d-aspartate receptor dysfunction.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) involves amyloid-beta (Aβ)-induced synaptic issues and calcium imbalance via N-methyl-d-aspartate (NMDA) receptors.
- Inorganic polyphosphate (polyP), released from activated platelets, shows potential in preserving neuronal survival.
Purpose of the Study:
- To investigate the neuroprotective effects of polyP against Aβ toxicity.
- To elucidate the mechanisms underlying polyP's action, focusing on calcium regulation and NMDA receptor function.
Main Methods:
- Primary rat neurons and PC12 cells were exposed to Aβ(25-35) and treated with sodium polyphosphate (Na-polyP).
- Assessed neuronal apoptosis, NMDA receptor-mediated calcium influx, and polyP-serotonin coacervate formation.
- Characterized release kinetics of polyP-based brain-targeted formulations.
Main Results:
- Aβ(25-35) induced significant neuronal apoptosis within 3 days.
- Na-polyP (50 µg/mL) completely prevented Aβ-induced neurotoxicity and reduced calcium influx.
- Na-polyP formed calcium-chelating coacervates with serotonin, mitigating Aβ-induced NMDA receptor sensitization.
Conclusions:
- Calcium chelation by polyP coacervates is a key mechanism protecting against Aβ neurotoxicity.
- PolyP-based formulations offer a promising, mechanistically supported therapeutic strategy for Alzheimer's disease.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Desensitization and Tachyphylaxis
Several...

